Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $19.11

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned a consensus recommendation of “Hold” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $19.1111.

FULC has been the topic of a number of research reports. Wall Street Zen cut Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Stifel Nicolaus set a $25.00 target price on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. JPMorgan Chase & Co. assumed coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Cantor Fitzgerald raised their price objective on shares of Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, December 8th.

Insiders Place Their Bets

In other news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider directly owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the sale, the director owned 469,864 shares in the company, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,205,139 shares of company stock valued at $58,711,943 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP bought a new position in shares of Fulcrum Therapeutics in the third quarter valued at approximately $35,000. Russell Investments Group Ltd. lifted its stake in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares in the last quarter. Assetmark Inc. bought a new position in Fulcrum Therapeutics in the 3rd quarter valued at $88,000. Finally, Vanguard Personalized Indexing Management LLC grew its position in shares of Fulcrum Therapeutics by 26.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after purchasing an additional 2,677 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Trading Down 2.7%

Fulcrum Therapeutics stock opened at $10.75 on Monday. The business’s 50 day simple moving average is $11.12 and its 200 day simple moving average is $8.98. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $15.74. The company has a market cap of $581.79 million, a price-to-earnings ratio of -9.11 and a beta of 3.20.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, equities research analysts forecast that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.